10-Q: Biora Therapeutics Reports Q2 2024 Results, Highlights NaviCap Clinical Trial Data

Biora Therapeutics reports a net income of $6.5 million for Q2 2024, driven by gains on warrant and derivative liabilities, while facing going concern doubts due to insufficient cash to fund operations for the next 12 months.

Summary

• Biora Therapeutics, a clinical-stage biotechnology company, filed its 10-Q report for the quarter ended June 30, 2024.
• The company is developing oral biotherapeutics using its NaviCap and BioJet platforms.
• For the six months ended June 30, 2024, Biora reported net income of $2.3 million, a significant improvement compared to the $35.2 million net loss in the same period of 2023.
• This was primarily due to gains on warrant and derivative liabilities.
• However, the company's cash used in operating activities was $23.4 million for the same period.
• As of June 30, 2024, Biora had cash and cash equivalents of $5.1 million and a working capital deficit.
• The company acknowledges substantial doubt about its ability to continue as a going concern for the next 12 months without raising additional capital.
• Management intends to raise additional capital through equity offerings, debt financings, or other sources.
• Biora's pipeline includes the NaviCap Targeted Oral Delivery Platform and the BioJet Systemic Oral Delivery Platform.
• Recent data from the Phase 1 clinical trial of BT-600, a drug/device combination using the NaviCap device with tofacitinib for ulcerative colitis, showed promising pharmacokinetic profiles and good tolerability.
• The company's accumulated deficit as of June 30, 2024, was $948.7 million.
• Revenues for the three months ended June 30, 2024, were $318,000, compared to $2,000 for the same period in 2023.
• Research and development expenses increased by $1.7 million for the three months ended June 30, 2024, compared to the same period in 2023.
• Selling, general, and administrative expenses decreased by $0.6 million for the three months ended June 30, 2024, compared to the same period in 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company reports net income for the quarter, it also expresses substantial doubt about its ability to continue as a going concern without additional funding. The positive clinical trial data is encouraging, but the financial situation raises concerns.

Positives

• Biora Therapeutics reported a net income of $6.5 million for Q2 2024, a significant improvement from the net loss of $17.8 million in Q2 2023.
• Phase 1 clinical trial data for BT-600 showed promising pharmacokinetic profiles and good tolerability, suggesting potential for targeted drug delivery.
• Revenues increased to $318,000 for the three months ended June 30, 2024, compared to $2,000 for the same period in 2023, indicating growth in collaboration revenue.
• The company is actively pursuing additional capital through equity offerings and debt financings.

Negatives

• Biora Therapeutics acknowledges substantial doubt about its ability to continue as a going concern for the next 12 months without raising additional capital.
• The company's cash and cash equivalents stood at $5.1 million as of June 30, 2024, which is deemed insufficient to fund operations for the next 12 months.
• The company's accumulated deficit as of June 30, 2024, was $948.7 million.
• The company has a working capital deficit.

Risks

• The company's ability to continue as a going concern is dependent on raising additional funding, which may not be available on acceptable terms or at all.
• Failure to raise capital could force the company to delay, reduce, or eliminate research and development programs.
• The company faces risks associated with clinical trials, regulatory approvals, and market acceptance of its product candidates.
• The company relies on third-party manufacturers and suppliers, and any disruptions could impact its ability to produce and deliver its products.
• The company operates in a highly competitive industry and faces the risk of intellectual property litigation.
• The company has outstanding convertible notes that could dilute the ownership interests of its stockholders.
• The company is subject to healthcare fraud and abuse regulations, and any violations could result in substantial penalties.
• The company is subject to risks associated with data security breaches and privacy violations.
• The company may fail to qualify for continued listing on The Nasdaq Global Market.

Future Outlook

Management intends to raise additional capital through equity offerings and/or debt financings, or from other potential sources of liquidity, which may include new collaborations, licensing or other commercial agreements for one or more of the Company's research programs or patent portfolios or divestitures of the Company's assets.

Industry Context

The company operates in the competitive biotechnology industry, focusing on oral biotherapeutics and drug delivery platforms, competing with major pharmaceutical and biotechnology companies.

Comparison to Industry Standards

• The report does not provide specific comparisons to industry standards or comparable companies.
• However, it mentions that the company's competitors have substantially greater financial and human resources.
• The company's success depends on its ability to develop products that are more effective than those of its competitors and to keep pace with rapid medical and scientific change.

Legal Proceedings

• The company is involved in a patent infringement suit filed by Ravgen, Inc. related to its discontinued historical laboratory developed test business.
• The company and plaintiffs agreed to settle the IPO litigation, subject to negotiation and entry into definitive and binding agreements and court approval, for an amount of $1.0 million.

Related Party Transactions

• Athyrium Capital Management, LP (Athyrium) held $18.4 million, including $1 million in PIK Notes, and $17.4 million aggregate principal amount of 2028 Convertible Notes.
• Athyrium also held 10,929,763 shares, or 30.4 %, of the Company's common stock outstanding, 7,399,226 pre-funded warrants and warrants to purchase up to 24,583,252 shares of common stock at exercise prices ranging from of $3.01 to $8.22 as of June 30, 2024.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees face uncertainty due to the company's financial situation and potential need to reduce operations.
• Customers may be impacted by potential delays or disruptions in product development and availability.
• Suppliers and creditors face increased risk due to the company's going concern doubts.

Next Steps

• The company intends to raise additional capital through equity offerings, debt financings, or other sources.
• The company will continue to advance the preclinical and clinical development of its lead targeted therapeutics and systemic therapeutics product candidates.
• The company will continue to develop, perfect and defend its intellectual property portfolio.

Key Dates

Keywords

Biora Therapeutics, NaviCap, BioJet, BT-600, Tofacitinib, Ulcerative Colitis, Clinical Trial, Going Concern, Convertible Notes, Drug Delivery, Biotherapeutics, Financial Results